Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Chemotherapy and Rituximab in Burkitt Lymphoma
NCT00126191Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2005
- Primary completion
- Dec 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in Burkitt lymphoma (BL), sponsored by Dana-Farber Cancer Institute. Started Jul 2005; status: terminated.
02
Drugs
rituximab
03
Conditions
Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT00126191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126191.